TrialDiabetes, obesity & metabolism2017

Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.

Carol Wysham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.